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Abstract
Parkinson’s disease (PD) is a common neurodegenerative disorder of unknown pathogenesis characterized by the loss of nigrostriatal
dopaminergic neurons. Oxidative stress, microglial activation and inflammatory responses seem to contribute to the pathogenesis. The
receptor for advanced glycation endproducts (RAGE) is a multiligand receptor of the immunoglobulin superfamily of cell surface molecules.
The formation of advanced glycation end products (AGEs), the first ligand of RAGE identified, requires a complex series of reactions
including nonenzymatic glycation and free radical reactions involving superoxide-radicals and hydrogen peroxide. Binding of RAGE
ligands results in activation of nuclear factor-kappaB (NF-B). We show that RAGE ablation protected nigral dopaminergic neurons against
cell death induced by the neurotoxin MPTP that mimics most features of PD. In RAGE-deficient mice the translocation of the NF-B subunit
65 to the nucleus, in dopaminergic neurons and glial cells was inhibited suggesting that RAGE involves the activation of NF-B. The
mRNA level of S100, one of the ligands of RAGE, was increased after MPTP treatment. The dopaminergic neurons treated with MPP and
S100 protein showed increased levels of apoptotic cell death, which was attenuated in RAGE-deficient mice. Our results suggest that
activation of RAGE contributes to MPTP/MPP-induced death of dopaminergic neurons that may be mediated by NF-B activation.
2012 Elsevier Inc. All rights reserved.
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Parkinson’s disease (PD) is a common neurodegenera-
tive disorder of mostly unknown etiology, with the excep-
tion of some genetically inherited cases. It is characterized
by disabling motor abnormalities, such as tremor, muscle
stiffness, paucity of voluntary movements, and postural
instability. Its primary neuropathological correlate is the
specific loss of the nigrostriatal dopaminergic neurons,
* Corresponding author. Tel.:44 1224 437325; fax:44 1224 437465.
E-mail address: p.teismann@abdn.ac.uk (P. Teismann).
0197-4580/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
10.1016/j.neurobiolaging.2011.12.006whose cell bodies reside in the substantia nigra pars com-
pacta (SNpc) and whose nerve terminals project to the
striatum (Przedborski et al., 2002). The subsequent deficit in
brain dopamine induces most of the clinical motor features
that are characteristic for the disease (Fahn and Przedborski,
2000).
Reactive oxygen species along with inflammatory pro-
cesses have been implicated in the pathogenesis of PD
(reviewed in Teismann and Schulz, 2004). Different fac-
tors have been linked to the induction of inflammation
and in PD pathogenesis, one of those being the nuclear-
factor-kappaB (NF-B) (Dehmer et al., 2004; Ghosh et
eL
o
2
g
w
e
p
n
n
A
S
l
K
y
w
t
R
m
a
A
r
2
t
2
2
b
h
w
m
B
U
2
o
d
M
m
d
w
t
h
3
c
w
e
2
g
s
G
C
G
T
a
t
U
2
c
c
v
2
a
u
2479P. Teismann et al. / Neurobiology of Aging 33 (2012) 2478–2490al., 2007; Hunot et al., 1997; Hunot et al., 1999). Previ-
ously it has been shown that ligation of the receptor for
advanced glycation endproducts (RAGE) leads to a sus-
tained activation of NF-B (Bierhaus et al., 2001). RAGE
xpression has been found to be increased in incidental
ewy Body disease and was linked to oxidative stress,
ne of the main factors implicated in PD (Dalfo et al.,
005). RAGE is a multiligand receptor of the immuno-
lobulin superfamily of cell surface molecules. RAGE
as first identified by its binding to advanced glycation
nd products (AGEs) (Kislinger et al., 1999). AGEs are a
roduct of a series of reactions, the initial one being
onenzymatic glycoxidation that is followed by mecha-
isms involving reactions with reactive oxygen species.
nother factor responsible for RAGE activation is the
100/calgranulin family of proinflammatory cytokine-
ike mediators (Donato, 1999; Hofmann et al., 1999;
erkhoff et al., 1998). Immunization of mice with meth-
lated serum albumin led to an inflammatory response
hich was inhibited by anti RAGE F(ab)=2 and anti-S100
F(ab)=2 fragment (Hofmann et al., 1999). A reduction in
NF-B activation was found in samples treated with
hese RAGE blockers, consistent with a central role for
AGE in generation of this inflammatory response (Hof-
ann et al., 1999). RAGE has also been proposed to be
mediator for amyloid- (A) peptide neurotoxicity in
lzheimer’s disease (Yan et al., 1996) as well as being
esponsible for pathogenic A assembly (Schmidt et al.,
001). Pathogenic A species are able to induce RAGE
expression in neurons, microglia and affected cerebral
vasculature. The A binding to RAGE has been shown to
induce oxidative stress, microglial activation and inflam-
matory responses. RAGE expression is usually dependent
on the presence of its ligands (S100, AGEs, A). As the
expression of these ligands is usually quite low, only
mature animals express RAGE, but in low concentra-
tions. However, the described ligands trigger the expres-
sion of RAGE (Brett et al., 1993; Park et al., 1998;
Ritthaler et al., 1995; Yan et al., 1996). An accumulation
of AGEs has not only been observed in Lewy bodies of
PD patients but also in incidental Lewy Body disease
(Munch et al., 2000), which is considered as a presymp-
tomatic state of PD. These data imply that AGEs/RAGE
may play an important role in the early stages of the
disease.
Insights into the pathogenesis of PD and potential effects
can be obtained by the use of the MPTP model of PD. The
MPTP is a by-product of the chemical synthesis of a me-
peridine analogue and can induce a parkinsonian syndrome
in humans almost indistinguishable from PD (Langston et
al., 1983). Using this model we investigated not only the
effect of RAGE-ablation on MPTP-induced toxicity, but
also whether NF-B translocation is attenuated in MPTP-
reated RAGE deficient mice.. Methods
.1. RAGE/ mice
RAGE/ mice were originally constructed on the
SVEV129xC57BL/6 (129/B6) background and backcrossed
into C57BL/6 mice as previously described in detail (Bier-
haus et al., 2004). Experiments were performed with
RAGE/ mice and wild type (wt) littermates after 10
ackcrosses. All mice were housed individually with a 12-
our/12-hour light/dark cycle with free access to food and
ater. Procedures in this study were approved by the Ani-
al Care and Use Committees at the Regierungspräsidium
raunschweig, Germany and the Home Office, Dundee,
K.
.2. Animals and treatments
Eight-week-old male RAGE deficient (RAGE/) mice
r their wt littermates were treated with either MPTP hy-
rochloride (Sigma, Deisenhofen, Germany) or saline.
PTP was administered in 0.1 ml of saline at a dose of 30
g/kg i.p. (free base) at 24 h intervals over 5 consecutive
ays. For each study, 4–10 mice were used per group and
ere killed at selected times ranging from 0 to 21 days after
he last injection. For HPLC measurements and tyrosine
ydroxylase (TH) immunohistochemistry, mice were killed
weeks after the last MPTP injection. Control mice re-
eived saline only. MPTP handling and safety measures
ere in accordance with published guidelines (Przedborski
t al., 2001).
.3. RNA extraction and RT-PCR
Total RNA was extracted from selected mouse brain re-
ions as described (Teismann et al., 2003). The primer mouse
equences were as follows: RAGE 5=-CTGAATCAGTCA-
AGGAAGC-3= (forward) and 5=-GGAGAAGGAAGTGC-
TCAAG-3= (reverse); S100 5=-GCTGACCACATGCCCCT-
TAG-3= (forward) and 5=-CTGGCCATTCCCCTCCTC-
GTC-3= (reverse), and GAPDH can be found in (Teismann et
l., 2003). All products were analyzed and quantified by real-
ime PCR (Taqman, Applied Biosystems, Foster City, CA,
SA).
.4. Anti-AGE and anti-RAGE monoclonal antibody
Preparation and characterization of the anti-AGE mono-
lonal and, polyclonal antibody and the anti-RAGE mono-
lonal antibody used in this study has been described pre-
iously (Makita et al., 1992; Srikrishna et al., 2002).
.5. Immunoblots
Mouse and human brain protein extracts were prepared
s described (Teismann et al., 2003). Primary antibodies
sed were as follows: RAGE (1:1000), AGE (1:1000) or
-actin (1:10,000; Sigma). A horseradish-peroxidase-con-
jugated secondary antibody (1:10,000-1:25,000; Amersham
Pharmacia, Freiburg, Germany) and a chemiluminescent
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were used for detection. Bands were quantified by using a
FluorChem 8800 digital image system (Alpha Innotech, San
Leandro, CA, USA).
2.6. RAGE, AGE, TH, p65, glial fibrillary acidic protein
(GFAP), BSI-IB4 and Iba1 immunohistochemistry
These were all performed according to our standard
protocol for single or double immunostaining (Teismann et
al., 2003). Primary antibodies were RAGE (1:100, Chemi-
con, Temecula, CA, USA), AGE (1:50), TH (1:1000;
Chemicon, Temecula, CA, USA-polyclonal; DiaSorin, Still-
water, MN, USA-monoclonal), GFAP (1:100; Dako, Ham-
burg, Germany), p65 (1:50; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and Iba1 (1:200; Wako Chemicals,
Neuss, Germany). Activated microglia were detected by
fluorescein isothiocyanate-labeled isolectin-B4 staining
(BSI-IB4; 1:20; Sigma). Immunostaining was visualized by
3,3=-diaminobenzidine. RAGE and AGE staining were vi-
sualized by anti-mouse cy2 (1:300; Biotrend, Cologne, Ger-
many). TH, GFAP and Iba1 staining were visualized by
anti-rabbit cy3 (1:300) (Figs 2 and 3). To assess the colo-
calization of TH-positive neurons and p65, TH was visual-
ized by anti-mouse cy2 (1:300), p65-staining was visualized
by anti-rabbit cy3 (1:200) (Fig. 5). For assessment of in-
crease of intracellular RAGE expression (see Fig. 2) sec-
tions were stained with mouse-anti-RAGE (1:1), visualized
with Alexa Fluor 488 antimouse (1:300; Molecular Probes,
Paisley, UK) and rabbit-TH (1:500) antibody, visualized
with anti-rabbit cy3 (1:300) (Fig. 1). TH immunostaining
was carried out on striatal and midbrain sections (Teismann
et al., 2003). All stainings were examined by either regular
light or confocal microscopy (LSM). The TH-stained and
Nissl-stained SNpc neurons were counted by stereology
using the optical fractionator method described (Teismann
et al., 2003). The striatal density of TH immunoreactivity
was determined as described (Teismann et al., 2003). The
p65 translocation was assessed 2 days or 5 days after the
first MPTP-injection as previously described (Dehmer et al.,
2004). Sections were assessed as for stereological cell
counts, but in this case for p65 localization. In all experi-
ments the observer was “blind” as to the experimental
condition of the animal.
2.7. Analysis of striatal dopamine levels and its
metabolites
Mice were sacrificed 21 days after the last MPTP-injec-
tion and striatal levels of dopamine and its metabolites,
dihydroxyphenylacetic acid (DOPAC) and homovanillic
acid (HVA), were measured by high-performance liquid
chromatography with electrochemical detection as previ-
ously described (Dehmer et al., 2004).2.8. MPTP metabolism
Striatal MPP levels were determined by HPLC-UV
detection (wavelength, 295 nm) (Teismann et al., 2003) 90
min after i.p. injection of 30 mg/kg MPTP.
2.9. Primary midbrain neuron cultures and
immunocytochemistry
The mesencephalic floor plate was dissected from E12
RAGE/ mice and wt littermates and further processed for
establishing dissociated cell cultures as previously de-
scribed (Lingor et al., 2000). Cells were seeded on poly-L-
ornithine/laminin (Sigma)-coated coverslips (10 mm diam-
eter) at a density of 120,000 cells/cm2. Cultures were
maintained at 37 °C in a humidified atmosphere and 5%
CO2 in DMEM/F12 (Pan-Biotech, Aidenbach, Germany)
lus the N1 supplements (Sigma) and antibiotics (Penicillin-
treptomycin-Neomycin (PSN) antibiotic Mixture (100X),
nvitrogen, Karlsruhe, Germany) for 6 days. Media was
hanged 24 hours after establishing cultures, designated as
ay in vitro (DIV) 1, and subsequently every second day.
On DIV4, S100 (A and B, S6552, Sigma) (100 ng/mL),
oncentrations obtained from (Li et al., 2000), and/or MPP
(2 g/mL) were applied for 24 hours. On DIV6 cells were
fixed with 4% paraformaldehyde (PFA) in PBS (pH 7.4). In
order to identify dopaminergic neurons in cultures, immu-
nocytochemical staining against TH was performed. To
reduce unspecific binding, diluted goat serum (10% in PBS)
was applied for 10 minutes at RT followed by incubation
with a polyclonal anti-TH antibody (1:1000; Chemicon) and
Hoechst 33258 (1:25,000; Molecular Probes, Karlsruhe,
Germany). For fluorescence labeling a secondary Cy-3-
labeled goat-anti-rabbit antibody (1:200; Biotrend) was
used. Coverslips were mounted on glass slides and observed
with a Zeiss Axioplan microscope.
TH-positive neurons and apoptotic nuclei were counted
at 40-fold magnification in 6 different areas per well. In cell
counts only TH-positive neurons possessing neurites were
considered as such to avoid distortion by nonfunctional yet
TH-positive cell debris. Cell survival is expressed as per-
centage standardized to the unchallenged and untreated con-
trol condition (100%). All experiments were performed at
least in duplicate with at least 3 wells in parallel. All
chemicals were freshly prepared and dissolved in cell cul-
ture medium immediately prior to application.
2.10. Statistical analysis
All values are expressed as the mean  SEM. Differ-
ences among means were analyzed by using one-way or
two-way ANOVA with time, treatment, or genotype as the
independent factor. When ANOVA showed significant dif-
ferences, pair-wise comparisons between means were tested
by Newman–Keuls post hoc testing. In all analyses, the null
hypothesis was rejected at the 0.05 level.
2481P. Teismann et al. / Neurobiology of Aging 33 (2012) 2478–2490Fig. 1. Ventral midbrain S100 and RAGE mRNA and RAGE and AGE protein expression after MPTP. S100 mRNA levels were increased by 0 days (A),
RAGE mRNA levels by 2 days (B), after MPTP injection. RAGE protein contents were low in saline-injected mice (sal) (C) but were increased 2 days after
MPTP treatment, whereas AGE expression remained unchanged (D). Striatal expression levels of RAGE and AGE remained unchanged (F–H), whereas
S100B mRNA expression was significantly increased in the striatum at 0 and 2 days after MPTP (ANOVA followed Newman–Keuls post hoc test).
Rcells (E
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3.1. MPTP induces RAGE and S100 expression in mouse
ventral midbrain
To determine whether the expression of RAGE or its
ligand S100 or AGE was affected during the nigrostriatal
neurodegeneration, we assessed the contents of S100
mRNA, RAGE mRNA and RAGE and AGE protein in
ventral midbrains (the brain region that contains the SNpc)
and striatum of saline- and MPTP-injected mice, at different
time points. Ventral midbrain S100, RAGE mRNA and
protein were detected in saline-treated mice and were
increased in MPTP-treated mice at day 0 and 2, respec-
tively, after the last of the 5 MPTP injections (Fig. 1
A–C), whereas we found no increase in the expression of
AGE (Fig. 1 D). In the striatum only S100 mRNA levels
were significantly increased (Fig. 1 E), but not RAGE
mRNA and protein as well as AGE protein levels (Fig. 1
F–H).
3.2. Induction of RAGE in SNpc dopaminergic neurons
after MPTP administration
To elucidate the cellular origin of RAGE up-regulation
in the ventral midbrain of MPTP-treated mice, we per-
formed immunohistochemistry. Two days after the last in-
Fig. 2. Ventral midbrain illustration of RAGE immunolocalization. RAGE-pos
A–C, 3D localization illustrated in D) and was also found in GFAP-positivejection, ventral midbrain RAGE immunostaining was de-tected to colocalize with TH staining in MPTP treated mice
(Fig. 2 A–C). A 3D localization revealed that RAGE ex-
pression is punctuate and can be found at the cellular mem-
brane (Fig. 2D). RAGE immunofluorescence did also colo-
calize with the microglial marker Iba1 (Fig. 2 E–G), and
with the astrocytic marker GFAP (Fig. 2 H–J). In striatal
staining RAGE expression was only detected in Iba1 posi-
tive cells (Fig. 3 G–J).
We then investigated the cellular localization of AGE, a
ligand for RAGE, after MPTP intoxication and found sim-
ilar results regarding the cellular localization. AGE immu-
nostaining was detected in dopaminergic neurons (Fig. 4
A–C), but AGE immunofluorescence did not colocalize
with the microglial marker Iba1 (Fig. 4 D–F), or with the
astrocytic marker GFAP (Fig. 4 G–I).
3.3. RAGE deficiency mitigates MPTP-induced
neurodegeneration
In light of the MPTP-induced up-regulation of RAGE
and its ligands, we asked whether this receptor is in-
volved in the nigrostriatal degeneration. Therefore, we
compared the effects of MPTP in RAGE/ and
AGE/ mice. Stereological counts of SNpc dopami-
nergic neurons defined by TH and Nissl staining did not
differ among the 2 genotypes after saline injections (Fig.
ls are abundant 2 d after MPTP, highly expressed in TH-positive neurons (red;
–G; red) and Iba1-positive cells (red; H–J; 3D localization illustrated in K).itive cel5, Table 1). SNpc dopaminergic neuron numbers were re-
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2483P. Teismann et al. / Neurobiology of Aging 33 (2012) 2478–2490duced in both genotypes after MPTP injections (Fig. 5 C
and D, Table 1). However, in RAGE/ mice significantly
more TH-stained SNpc neurons survived MPTP adminis-
tration than in RAGE/ mice (Fig. 5, Table 1) (p 0.035).
PTP-treated groups showed a high significant difference
p  0.001) when compared vs. saline controls (F value 
3.438, degrees of freedom: between groups: 3, residual:
4, total: 17).
Loss of Nissl-positive cells confirmed, that the loss of TH-
ositive neurons corresponds to an actual loss of neurons
RAGE/ mice  saline  14,520  527, RAGE/
mice  saline  15,450  810, RAGE/ mice MPTP 
7747 375 and RAGE/ mice  MPTP  9653  465).
n the striatum, the density of TH-positive fibers was
ecreased to 32.3% of saline values in MPTP-treated
AGE/ and to 35.6% in RAGE/ mice (Table 1).
MPTP-treated groups showed a high significant differ-
ence (p  0.001) when compared vs. saline controls (F
value  42.801, degrees of freedom: between groups: 3,
residual: 14, total: 17). RAGE ablation also provided
partial protection against the MPTP-induced loss of do-
pamine (p  0.0499) and DOPAC (p  0.021) but not
gainst the loss of HVA in the striatum (Table 2).
MPTP-treated groups showed a high significant differ-
nce (p  0.001) when compared vs. saline controls (do-
Fig. 3. Striatal illustration of RAGE immunolocalization. Iba1-positive ce
MPTP. RAGE does not seem to be localized in TH-positive fibers (red; Aamine: F value  57.121, degrees of freedom: between iroups: 3, residual: 13, total: 16; DOPAC: F value 
4.406, degrees of freedom: between groups: 3, residual:
2, total: 15; HVA: F value  2.772, degrees of freedom:
etween groups: 3, residual: 9, total: 12).
RAGE deficiency reduces NF-B p65 translocation. Ac-
ivation of NF-B is a downstream signal of RAGE. We
therefore investigated the translocation of the p65 subunit of
NF-B to the nucleus, which demonstrates the activation of
NF-B and is a prerequisite for its transcriptional activity.
In controls, immunoreactivity for the NF-B subunit p65/
RelA was almost exclusively located in the cytosol, where
it colocalized with TH (Fig. 6) and BSI-IB4 expression. In
contrast, in MPTP-treated animals the p65/RelA immuno-
reactivity was translocated to the nucleus in TH-positive
and IB4-positive cells. RAGE/ mice showed a reduced
ranslocation of p65 to the nucleus in TH-positive and
SI-IB4-positive cells (Fig. 6).
.4. RAGE deficiency mitigates microglia and
strocytic activation
As shown previously (Dehmer et al., 2004), BSI-IB4
mmunostaining revealed a robust increase in the amount of
ctivated microglia in the striatum and the SNpc after 2 and
doses of MPTP (Table 3). We also observed a marked
; G–I; 3D localization illustrated in J) show RAGE expression 2 d after
GFAP-positive cells (D–F; red).lls (redncrease of astrocytes in the striatum and SNpc (Table 3).
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2484 P. Teismann et al. / Neurobiology of Aging 33 (2012) 2478–2490RAGE/ mice showed reduced activation of microglia and
less GFAP-positive cells in both striatum and SNpc after 2
and 5 injections of MPTP (Table 3).
3.5. RAGE deficiency does not impair MPTP metabolism
in F10 generation
To ascertain that resistance to the neurotoxic effects of
MPTP provided by RAGE deficiency was not due to alter-
ations in MPTP metabolism, we measured concentration of
MPP in striatal lysates 90 minutes after one injection of
MPTP (30 mg/kg i.p.). MPTP metabolism was not signifi-
cantly different in wt and RAGE/-mice. Striatal levels of
PP were not lower in MPTP-injected RAGE/ mice
ompared with RAGE/ mice (RAGE/ mice  14.1 
Fig. 4. Ventral midbrain illustration of AGE immunolocalization. As RAG
in TH-positive neurons (red; A–C) and not in Iba1-positive cells (D–F; re.98 and RAGE/ mice  14.7  0.84 g/g wet tissue peight). Mice of this F10 generation were used for all
xperiments presented here.
.6. RAGE deficiency protects against S100 and MPP
induced toxicity
To study the role of RAGE in S100- and MPP induced
oxicity, primary dopaminergic neurons from RAGE/ mice
and their wt littermates were exposed to S100 (100 ng/mL)
and/or MPP (2 M for 24 hours). Primary TH-positive neu-
rons derived from RAGE-deficient mice were almost com-
pletely protected from S100 induced cell loss and partially
protected from MPP induced toxicity. The combination of
100 and MPP induced more toxicity then either treatment
lone in wild type animals. RAGE deficiency provided partial
ssion, AGE-positive cells are abundant 2 d after MPTP, highly expressed
FAP-positive cells (G–I; red).E-exprerotection from combined S100/MPP toxicity (Fig. 7).
le
2485P. Teismann et al. / Neurobiology of Aging 33 (2012) 2478–24904. Discussion
Multiple factors have been implicated in the pathogenesis
of PD and associated with MPTP-induced neurotoxicity. In
this study we show an up-regulation of RAGE and microglia in
the SNpc of mice treated with the neurotoxin MPTP. Signifi-
cant alterations were not observed in the striatum, but this can
be due to the fact that dopaminergic synapses only represent
less than 15% of striatal structures (Pickel et al., 1981; Ten-
nyson et al., 1974). RAGE expression was mainly present in
TH-positive neurons and microglia, while its ligand AGE
could mainly be detected in TH-positive neurons. Engagement
of RAGE has been reported to magnify cell stress in different
pathological settings (Stern et al., 2002). Rage-AGE interac-
tion has been linked to the binding of amyloid fibers in Alz-
heimer’s disease as well as propagating neurotoxic features of
Fig. 5. Effect of RAGE ablation on MPTP-induced neuronal loss. TH-pos
RAGE/ mice (A and B). TH-positive neurons are more resistant to MPT
after MPTP. TH-positive neuronal counts are quantified in Table 1.
Table 1
Effect of RAGE ablation on MPTP-toxicity
SNpc: no. of TH-positive neurons
RAGE/ RAGE/
Saline 10200  266 10253 
MPTP 4640  103* 5472 
Values are mean  SEM for four to six mice per group.
ANOVA followed by Newman–Keuls post hoc test.
* p  0.001 compared with the other groups of saline-treated mice.
† p  0.035 compared with MPTP-injected RAGE/ mice.amyloid fibers (Yan et al., 1996). In addition, activation of
RAGE has been linked to neuronal dysfunctions in diabetes,
since activation of the RAGE-NF-B axis contributes to the
oss of pain perception in diabetic mice. Consistently, NF-B
activation and loss of pain perception are significantly reduced
in streptozotocin-induced diabetic RAGE/-mice (Bierhaus
t al., 2004).
In PD, a 70-fold increase of NF-B activation in
melanized midbrain neurons has been reported (Hunot et al.,
1997). Furthermore, we have previously demonstrated that
MPTP-administration leads to increased translocation of
p65 to the nucleus in TH-positive neurons and glial cells
(Dehmer et al., 2004). Since RAGE and RAGE-ligands
accumulate in PD, the data led us to hypothesize that
RAGE-dependent sustained NF-B activation might con-
ls of the SNpc appear comparable between saline-injected RAGE/ and
GE/ (D) than in RAGE/ (C) mice. Cell counting was performed 21 d
Striatum: TH-positive fibers, OD  100
RAGE/ RAGE/
24.41  0.75 24.71  2.07
7.89  1.04* 8.80  0.96*itive cel
P in RA
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2486 P. Teismann et al. / Neurobiology of Aging 33 (2012) 2478–2490tribute to the outcome of the disease. Consistently, the
MPTP-mediated translocation of p65 was reduced in
RAGE/-mice. RAGE/-mice treated with MPTP
showed more surviving dopaminergic neurons than their
control littermates. Also primary dopaminergic neurons
from RAGE/-mice were partially protected against
MPP induced cell death. These data implicate a role for
AGE mediated NF-B translocation in MPTP-induced
oxicity. The “classic” NF-B-heterodimer consists of two
proteins of 50 and 65 kDA, referred to as p50 and p65/RelA,
Table 2
Striatal concentrations of catecholamines
Dopamine DOPAC HVA
AGE/  saline 15.80  0.42 3.13  0.19 0.92  0.02
AGE/  saline 15.34  1.46 2.95  0.16 1.04  0.15
AGE/  MPTP 4.15  0.64* 1.12  0.12* 0.73  0.02*
AGE/  MPTP 6.38  0.25*,† 1.68  0.08*,# 0.81  0.04*
RAGE/mice are partially protected from MPTP-induced decrease of
striatal dopamine and DOPAC concentrations at 21 days after the last MPTP
injection, but are not protected against decrease of HVA. Values are mean 
SEM for 3 to 6 mice per group.
ANOVA followed by Newman–Keuls post hoc test.
* p  0.001 compared with the other groups of saline-treated mice.
† p  0.0499 compared with MPTP-injected RAGE/ mice.
# p  0.021 compared with MPTP-injected RAGE/ mice.
Fig. 6. Effects of RAGE ablation on MPTP-induced NF-B translocation i
antibody reactive against the p65/RelA subunit of NF-B in the substantia
MPTP (MPTP), and RAGE/ mice treated with MPTP. Quantification (%
n striatum that show translocation of p65/RelA staining from the cytoso
AGE/ mice. *p  0.05 compared with RAGE/ mice (n  5) (ANOVA forespectively (for review see (Janssen and Sen, 1999; O’Neill
and Kaltschmidt, 1997)). Surprisingly, ablation of the sub-
unit p50 did not provide any beneficial effects in MPTP-
induced toxicity (Teismann et al., 2001). As mice deficient
in the p65/RelA subunit of NF-B are embryonically lethal
Beg et al., 1995), no data exists on the function of the
65/RelA subunit of NF-B MPTP toxicity. Very recently
t has been shown that inhibition of NF-B activation by
he use of NF-B essential modifier-binding domain pep-
tides (NBDs) provides neuroprotection against MPTP-
induced toxicity, by preventing the expression of proin-
flammatory molecules (Ghosh et al., 2007), thus
demonstrating a role for NF-B in the MPTP-model of
D. S100B could be one of the factors involved in NF-B
activation, as it can activate p65/c-Rel transcription in a
RAGE dependent manner (Kogel et al., 2004). Moreover,
NF-B mediates neuronal nitric oxide synthase (nNOS)
nduction in a cellular model of MPTP-toxicity (Carbone
t al., 2008). Furthermore, inhibition of NF-B with
1,1-bis(3=-indolyl)-1-(p-t-butylphenyl)methane resulted
in a reduction of caspase activity and nNOS activation
(Carbone et al., 2009). Overall, a partially reduced
NF-B activation, but not total inhibition, could be an
xplanation for the lesser effect observed on loss of
H-positive neurons after MPTP.
ositive neurons and glial cells. Costaining of TH-positive neurons with an
f animals that were left untreated (control), wild type animals treated with
-positive neurons and IB4-positive cells in the SNpc and IB4-positive cells
nucleus after 2 and 5 doses of MPTP and block of this translocation inn TH-p
nigra o
) of TH
l to thellowed by Tukey’s post-hoc test).
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2487P. Teismann et al. / Neurobiology of Aging 33 (2012) 2478–2490Since RAGE expression was found in TH-positive do-
paminergic neurons it was surprising that RAGE-deficiency
did not extend its neuroprotective effect to striatal dopami-
nergic fibers. It has been reported that glial changes are
more significant to MPTP-induced cell death in the SNpc
than in the striatum (Liberatore et al., 1999) due to their
proximity to dopaminergic structures and are more robust in
the SNpc (Teismann and Schulz, 2004). In our study the
protective profile mediated by RAGE deficiency did not
extend to striatal dopaminergic fibers but also RAGE ex-
pression was not affected by MPTP significantly in the
striatum (Fig. 1). The neurites seem to be more prone to
toxic insults as different studies using MPTP-induced cell
death indicate. In many former studies interfering with
Table 3
Numbers of IB 4 and GFAP positive cells in striatum and SNpc
Striatum
IB 4-positive G
wt  saline
RAGE/  saline
wt  MPTP 2x 86.1  5.7
RAGE/  MPTP 2x 77.5  2.9
wt  MPTP 5x 79.0  4.0 1
RAGE/  MPTP 5x 62.0  4.0
Treatment with two (2x) or five (5x) doses of MPTP activated microglia (I
This activation was reduced in RAGE/ mice. Data are mean  SEM, in
no IB 4 positive cells were detected.
ANOVA followed by Newman–Keuls post hoc test.
* p  0.05 compared with MPTP treated wild type mice.
Fig. 7. Treatment of primary dopaminergic neurons from RAGE/
mice with MPP resulted in a reduced number of cell showing apoptotic
uclei when compared with cells from wild type controls. MPP toxicity
was enhanced, when primary dopaminergic neurons from RAGE/ mice
here cotreated with S100, but not in cells from RAGE/ mice. *, p 
0.05, cells from RAGE/ mice compared with corresponding treatment of
ells from RAGE/ mice (ANOVA followed by Newman–Keuls post hoc
est).apoptotic or inflammatory pathways in MPTP-induced cell
death resulted in protective effects on dopaminergic somata
of the SNpc but not on striatal dopaminergic terminals
(Dehmer et al., 2000; Liberatore et al., 1999; Tieu et al.,
2004). Dopamine content was partially rescued in RAGE
deficient animals, indicating that even though there was no
significant change in numbers of dopaminergic terminals,
functionality of the neurons was sustained.
The MPTP-protocol, which used (5 30 mg/kg i.p.) also
leads to an inflammatory response contributing to the cell
death process. Despite the fact that microglia can be bene-
ficial reports using the MPTP-model describe a deleterious
effect associated with the activation of microglia (Wu et al.,
2003). In humans MPTP leads to a slowly progressive
degeneration as demonstrated in a study of MPTP intoxi-
cated patients, which revealed an active ongoing degenera-
tive and inflammatory process in the SNpc 3–16 years after
MPTP exposure (Langston et al., 1999).
The MPTP leads to a time-dependent increase in expres-
sion of S100B, another ligand of RAGE, localized in astro-
cytes (Fig. 2) (Himeda et al., 2006; Muramatsu et al., 2003).
S100B, the predominant form of S100 in the brain is both
neuroprotective and neurotoxic, depending on the dose
(Huttunen et al., 2000). RAGE activation by nanomolar
S100B leads to an increased expression of the antiapoptotic
protein Bcl-2 whereas in micromolar concentration S100B
induces apoptosis in an oxidant and MAP-kinase dependent
manner (Huttunen et al., 2000).
Interestingly we found a large decrease after a significant
rise in S100B and RAGE mRNA levels in the SNpc. We can
only hypothesize that S100B might lead to self-inhibition
through a feed-back loop after the initial increase. The same
could also hold true for RAGE, but it might also be related
to the loss of TH-positive neurons, as these numbers are
significantly reduced. As low levels of S100B expression is
associated with neuroprotection, the underlying mechanism
could also be compensatory, to protect the remaining neu-
rons due to lowered S100B expression. Nevertheless, these
SNpc
ositive IB 4-positive GFAP positive
3.3 20.7  1.2
0.6 18.2  2.6
15.9 98.5  9.5 127  14.8
1.1* 89.3  7.3 44.1  5.6*
7.5 103.0  12.1 107.6  11.8
7.0* 87.5  5.8* 63.7  2.6*
itive cells) and astrocytes (GFAP positive cells) in the striatum and SNpc.
r of IB 4 or GFAP-positive cells within an area of 0.25 mm2. In controls,FAP p
9.5 
8.1 
84.8 
46.8 
04.4 
66.0 
B4-pos
numbefindings will need further investigation.
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2488 P. Teismann et al. / Neurobiology of Aging 33 (2012) 2478–2490The authors (Himeda et al., 2006; Muramatsu et al.,
2003) suggest, that GFAP-positive astrocytes, which secrete
S100B, participate in MPTP-induced toxicity, and thus in
the pathogenesis of PD. S100B is capable of activating
COX-2, but this depends on the presence of RAGE (Bianchi
et al., 2010).
We also detected a reduced number of microglia in
MPTP-treated RAGE/ mice, indicating, that the inflam-
matory process was attenuated due to RAGE ablation. Pre-
ceding reports have linked microglia activation with MPTP-
induced toxicity (Wu et al., 2002; Wu et al., 2003), which in
turn has been linked to the formation of inducible nitric
oxide synthase (iNOS) (Dehmer et al., 2000; Liberatore et
al., 1999). Furthermore, we found a reduction in microglia
showing p65 translocation, implying that iNOS expression
might be reduced as described (Dehmer et al., 2004). This
may lead to the increased number of surviving dopaminer-
gic neurons seen in RAGE/ mice. Microglia activation
eems to be secondary to neuronal damage, and thus RAGE
blation might not mediate a very pronounced neuroprotec-
ive effect.
As we found a rather weak effect of neuroprotection due
o RAGE ablation, we hypothesize that this pathway is only
arginally involved in the neurodegenerative process, es-
ecially as COX-2 ablation shows a more profound neuro-
rotective effect in a more severe model (Teismann et al.,
003). However, S100B was also shown to activate p38,
RK1/2 and JNK in Alzheimer’s disease (Kim et al., 2004),
f which S100B mediated JNK and ERK1/2 activation
eems again be dependent on the presence of RAGE (Bi-
nchi et al., 2010). As mice lacking JNK showed a more
ronounced neuroprotective effect then we observed in
AGE/ mice (Hunot et al., 2004), it seems unlikely that
AGE activates the JNK pathway in the MPTP model.
Another factor, which could contribute to RAGE activa-
ion is its ligand high mobility group Box 1 (HMGB1). This
rotein is released from necrotic and inflammatory cells
eading to an inflammatory response (Lotze and Tracey,
005), features seen in PD and the MPTP-model. It has also
een shown that in stroke inhibition of HMGB1 release as
ell as RAGE ablation leads to a neuroprotective effect
Muhammad et al., 2008). The data show, that RAGE ex-
ression on glial cells mediates HMGB1 effects (Muham-
ad et al., 2008), which could also be the case in the
PTP-model.
In a final set of experiments we tested the influence of the
igand S100 on survival of dopaminergic neurons. Addition
f S100 to dopaminergic neurons led to increased cell death
nd also increased MPP mediated neurotoxicity. Using
rimary dopaminergic neurons from RAGE/ mice we
ere able to ablate the deleterious effect mediated by the
ddition of S100, although not to full extend. But RAGE is
ot the only mediator of S100, as S100 also activates a
ultitude of other factors, most importantly iNOS (Hu etl., 1996) and interleukin-1 (IL-1) (Koppal et al., 2001).It is very likely, that part of the neurotoxic effect after
MPP is mediated by these targets of S100B, which do not
require RAGE.
Our results further support the evidence for inflammatory
processes contributing to MPTP-induced cell death. They sug-
gest a role for RAGE-mediated microglia response and subse-
quently RAGE-mediated cell death in MPTP-induced neuro-
toxicity. Treatment strategies aimed at inhibiting the
inflammatory response in connection with blocking RAGE
could prove beneficial in halting/slowing the progression of
PD.
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